![]() |
|
|
Vol. 289, Issue 3, 1323-1333, June 1999
Unit on Cell Biology, Determination of ligand-binding constants for parathyroid hormone (PTH)
receptors has been hampered by a lack of suitable experimental systems
and mechanistic models for data analysis. In this study, ligand binding
to the cloned human PTH-1 receptor was measured using membrane-based
radioligand-binding assays. Guanosine
5'-O-(3-thiotriphosphate) (GTP
S) (10 µM) reduced
binding of agonist radioligands [125I]rPTH(1-34) and
[125I]PTHrP(1-36) but only to a limited extent (by
29 ± 5 and 42 ± 3%, respectively). Radiolabeled agonist
dissociation was described by three and two phases in the absence and
presence of GTP
S, respectively. GTP
S treatment removed a
pseudoirreversible binding phase. Inhibition of radiolabeled antagonist
([125I]bPTH(3-34)) binding was measured using a 90-min
incubation, which allowed binding of ligands to closely approach the
asymptotic maximum. Agonist/[125I]bPTH(3-34)
displacement curves were fitted best by assuming two independent
affinity states, both in the presence and absence of GTP
S. After a
3-h incubation, binding of PTH agonists in the presence of GTP
S was
described by a single affinity state, indicating the presence of slow
components in the binding reaction. Antagonist binding was described by
a single affinity state and was not significantly affected by GTP
S.
The data were used to evaluate potential receptor-binding models.
Although other models could not be excluded, all of the observations
could be explained by assuming two binding sites on the receptor that
recognize two corresponding sites on agonist ligands. Using the model,
it was possible to estimate receptor-ligand-binding constants and to
propose a direct method for identifying ligands that interact with a
putative antagonist binding region of the receptor.
0022-3565/99/2893-1323$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by U.S. Government